Ribomic Inc.
JPX: 4591.T0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Tokyo Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Yoshikazu Nakamura
- Employees
- 24
- Headquarters
- Tokyo, Japan
- IPO year
- 2014
- Market cap
- ¥4.2B
- Website
- https://www.ribomic.com
Loading 4591…
Loading profile data…Frequently asked questions about 4591
What does Ribomic Inc. (4591.T) do?
Ribomic Inc. discovers and develops pharmaceutical compounds using RNA aptamers in Japan. The company develops drugs for wet age-related macular degeneration, achondroplasia, pulmonary arterial hypertension, proliferative vitreoretinopathy, heart failure, osteoarthritis, and asthma, as well as separating agents for affinity purification of human...
Where does 4591.T trade?
Ribomic Inc. (4591.T) trades on the Tokyo Stock Exchange.
What sector is 4591.T in?
Ribomic Inc. (4591.T) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Ribomic Inc.?
Yoshikazu Nakamura is the chief executive officer of Ribomic Inc. (4591.T).
Where is Ribomic Inc. headquartered?
Ribomic Inc. is headquartered in Japan.
Does 4591.T pay a dividend?
Ribomic Inc. (4591.T) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 4591.T go public?
Ribomic Inc. (4591.T) completed its initial public offering in 2014.